Tuberculosis Drugs Market

Tuberculosis Drugs Market – Overview

The global tuberculosis drugs market is anticipated to witness massive growth during the forecast period (2021 to 2031). Tuberculosis is a chronic illness that has become a global health concern. Manufacturers of tuberculosis drugs are focusing on creating drugs that can reduce treatment time and assist in overcoming the obstacles of drug-susceptible and drug-resistant tuberculosis. There are three forms of tuberculosis treatment: first-line treatment, second-line treatment, and drug-resistant treatment.

Although advanced technologies and the development of novel therapeutics are expected to shorten the time of therapy for tuberculosis, most occurrences of tuberculosis with currently available drugs can require up to 6 months of treatment. Moreover, despite existing medicines and continuing tuberculosis treatment drug advances, there is a constant need to increase patients' access to suitable tuberculosis medicines, especially in the areas of multidrug-resistant tuberculosis and pediatric tuberculosis.

Tuberculosis Drugs Market – Competitive Landscape

Key players active in the worldwide tuberculosis drugs market are Macleods Pharmaceuticals Ltd., Johnson & Johnson Services, Otsuka Pharmaceutical Co., Ltd, LLC, Lupin Ltd, Novartis AG, Pfizer Inc., and others.

Key market participants are focused on strategic collaborations to market newly developed medications. For example, Mylan, a pharmaceutical company, cooperated with TB Alliance to launch the Pretomanid medication for treating pulmonary tuberculosis.

Tuberculosis Drugs Market – Trends and Opportunities

The factors expected to drive the global tuberculosis drugs market include a high frequency of drug-susceptible tuberculosis, a rise in multi-drug resistant tuberculosis patients, and a boost in R&D activities toward medication discovery. Furthermore, cooperation between international organizations such as the United, WHO, UNICEF, and the TB Alliance focused on developing shorter treatment regimens to combat drug resistance is projected to boost the global tuberculosis drugs market.

Moreover, the growing number of drug developments is expected to propel the global tuberculosis drugs market during the forecast period. The TB Alliance, a non-profit organization based in the United States, has produced a novel medicine for the treatment of drug-resistant tuberculosis. For example, in August 2019, TB Alliance got FDA clearance for Pretomnid, a linezolid and bedaquiline combination regimen developed and intended for the treatment of patients with extensively drug-resistant tuberculosis or intolerant non-responsive multi-drug resistant tuberculosis.

Furthermore, the growing prevalence of tuberculosis around the world is projected to bolster the global tuberculosis drugs market. According to the World Health Organization's Global Tuberculosis Report 2018, approximately 10 million individuals globally died from tuberculosis in 2017.

Tuberculosis Drugs Market – Regional Landscape

The Asia Pacific tuberculosis drugs market is expected to witness considerable growth during the forecast period. The growth can be linked to the disease's high prevalence, rising incidence of HIV-TB co-infection, increased population knowledge of the dangers of drug compliance and improved healthcare infrastructure. Moreover, India and China are expected to make significant contributions to the regional market.

The tuberculosis drugs market in Europe and North America is expected to rise during the forecast period. Europe is home to nine high-risk nations, with multi-drug resistant and extensively drug-resistant tuberculosis prevalence rates rising. According to WHO, the region has the largest number of new multi-drug resistant tuberculosis cases, with 71,000 new cases reported in 2016. The fundamental cause of the rise in drug-resistant forms of the disease is inadequate treatment.

Although North America has a low incidence rate of drug-susceptible tuberculosis, a growing immigrant population necessitates a larger emphasis on LTBI screening measures. Efforts to control the development of the latent disease type have risen in the United States and Canada, where a substantial proportion of the population is foreign. This is anticipated to improve the region's market for latent tuberculosis treatments.